STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #288 by analyst upside · 2026-06-27
IVA
Inventiva S.A.
Healthcare · Market Cap $806M · P/E 0x
ANALYST PRICE TARGET
+343.6%
implied upside to consensus target
Current Price $3.41
Consensus Target $15.13
Bull Target $26.0
Bear Target $8.8
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
0
Sell
0
52-Week Low $2.85
52-Week High $7.98
YTD Return -28.4%
FUNDAMENTALS
Market Cap $806M
P/E Ratio (TTM) N/A
Forward P/E -3.9x
EPS (TTM) $-2.16
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $7M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.85
52-Week High $7.98
Current Price $3.41
Bear Target $8.8
Bull Target $26.0
● Now $3.41 ● Target $15.13
TRADING DATA
Avg Volume 599K
YTD Return -28.4%
Analyst Count 13
Consensus Buy
Upside to Target +343.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Inventiva S.A. (IVA) is currently trading at $3.41 with a Wall Street consensus price target of $15.13, implying potential upside of 343.6% over the next 12 months. 13 analysts currently cover IVA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $8.8.

IVA operates in the Healthcare sector with a market capitalisation of $806M. The stock is down 28.4% year-to-date and is currently trading near the lower end of its 52-week range of $2.85 – $7.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities ● Initiated
Buy 2026-03-19 Building track record
Barclays ● Initiated
Overweight 2026-01-28 Building track record
Leerink Partners ● Initiated
Outperform 2026-01-12 29% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2025-11-18 62% win rate (8 calls)
Wolfe Research ● Initiated
Outperform 2025-11-06 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-10-09 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-09-30 Building track record
Guggenheim — Reiterated
Buy → Buy 2025-09-02 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →